癌症研究
膀胱癌
顺铂
糖酵解
癌症
过剩1
葡萄糖转运蛋白
癌细胞
活力测定
己糖激酶
葡萄糖摄取
生物
厌氧糖酵解
医学
细胞凋亡
内科学
肿瘤科
化疗
新陈代谢
生物化学
胰岛素
作者
Julieta Afonso,Céline S. Gonçalves,Marta Freitas Costa,Débora Ferreira,Lúcio Lara Santos,Adhemar Longatto‐Filho,Fátima Baltazar
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2023-02-03
卷期号:15 (3): 982-982
被引量:56
标识
DOI:10.3390/cancers15030982
摘要
Proliferating cancer cells are able to reprogram their energy metabolism, favouring glycolysis even in the presence of oxygen and fully functioning mitochondria. Research is needed to validate the glycolysis-related proteins as prognostic/predictive biomarkers in urothelial bladder carcinoma (UBC), a malignancy tagged by high recurrence rates and poor response to chemotherapy. Here, we assessed GLUT1, HK2, PFKL, PKM2, phospho-PDH, and LDHA immunoexpression in 76 UBC samples, differentiating among urothelial, fibroblast, and endothelial cells and among normoxic versus hypoxic areas. We additionally studied the functional effects of the HK2 inhibitor 2-deoxy-D-glucose (2DG) in "in vitro" and "in vivo" preclinical UBC models. We showed that the expression of the glycolysis-related proteins is associated with UBC aggressiveness and poor prognosis. HK2 remained as an independent prognostic factor for disease-free and overall survival. 2DG decreased the UBC cell's viability, proliferation, migration, and invasion; the inhibition of cell cycle progression and apoptosis occurrence was also verified. A significant reduction in tumour growth and blood vessel formation upon 2DG treatment was observed in the chick chorioallantoic membrane assay. 2DG potentiated the cisplatin-induced inhibition of cell viability in a cisplatin-resistant subline. This study highlights HK2 as a prognostic biomarker for UBC patients and demonstrates the potential benefits of using 2DG as a glycolysis inhibitor. Future studies should focus on integrating 2DG into chemotherapy design, as an attempt to overcome cisplatin resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI